Logo

Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop… read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$43.15

Price

+4.05%

$1.68

Market Cap

$4.401b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-33.3%

3y CAGR

-5.9%

5y CAGR
Earnings

-$353.428m

-43.5%

1y CAGR

-38.4%

3y CAGR

-29.3%

5y CAGR
EPS

-$3.22

-30.4%

1y CAGR

-14.8%

3y CAGR

-1.5%

5y CAGR
Book Value

$244.995m

$411.718m

Assets

$166.723m

Liabilities

$110.076m

Debt
Debt to Assets

26.7%

-0.3x

Debt to EBITDA
Free Cash Flow

-$274.644m

-36.6%

1y CAGR

-27.9%

3y CAGR

-21.2%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases